BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 24510314)

  • 21. Primary Analysis and 4-Year Follow-Up of the Phase III NIBIT-M2 Trial in Melanoma Patients With Brain Metastases.
    Di Giacomo AM; Chiarion-Sileni V; Del Vecchio M; Ferrucci PF; Guida M; Quaglino P; Guidoboni M; Marchetti P; Cutaia O; Amato G; Covre A; Camerini R; Calabrò L; Valente M; Giannarelli D; Mandalà M; Maio M
    Clin Cancer Res; 2021 Sep; 27(17):4737-4745. PubMed ID: 34112708
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fotemustine in the treatment of brain primary tumors and metastases.
    Khayat D; Giroux B; Berille J; Cour V; Gerard B; Sarkany M; Bertrand P; Bizzari JP
    Cancer Invest; 1994; 12(4):414-20. PubMed ID: 8032964
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Contribution of a new nitrosourea compound: fotemustine].
    Boaziz C
    Pathol Biol (Paris); 1992 Dec; 40(9 Pt 2):964-8. PubMed ID: 1338920
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Temozolomide in combination with fotemustine in patients with metastatic melanoma.
    Tas F; Camlica H; Topuz E
    Cancer Chemother Pharmacol; 2008 Jul; 62(2):293-8. PubMed ID: 17909803
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Immunochemotherapy of metastatic uveal melanoma with interferon alfa-2b, interleukin-2 and fotemustine. Case reports and review of the literature].
    Terheyden P; Kämpgen E; Rünger TM; Bröcker EB; Becker JC
    Hautarzt; 1998 Oct; 49(10):770-3. PubMed ID: 9857252
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prolonged survival after resection of liver metastases from uveal melanoma and intra-arterial chemotherapy.
    Kodjikian L; Grange JD; Rivoire M
    Graefes Arch Clin Exp Ophthalmol; 2005 Jun; 243(6):622-4. PubMed ID: 15650857
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Meta-analysis in metastatic uveal melanoma to determine progression free and overall survival benchmarks: an international rare cancers initiative (IRCI) ocular melanoma study.
    Khoja L; Atenafu EG; Suciu S; Leyvraz S; Sato T; Marshall E; Keilholz U; Zimmer L; Patel SP; Piperno-Neumann S; Piulats J; Kivelä TT; Pfoehler C; Bhatia S; Huppert P; Van Iersel LBJ; De Vries IJM; Penel N; Vogl T; Cheng T; Fiorentini G; Mouriaux F; Tarhini A; Patel PM; Carvajal R; Joshua AM
    Ann Oncol; 2019 Aug; 30(8):1370-1380. PubMed ID: 31150059
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fotemustine chemoembolization of hepatic metastases from uveal melanoma: a retrospective single-center analysis.
    Edelhauser G; Schicher N; Berzaczy D; Beitzke D; Höeller C; Lammer J; Funovics M
    AJR Am J Roentgenol; 2012 Dec; 199(6):1387-92. PubMed ID: 23169735
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fotemustine for the treatment of melanoma.
    Quéreux G; Dréno B
    Expert Opin Pharmacother; 2011 Dec; 12(18):2891-904. PubMed ID: 22077794
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Therapy of metastatic malignant uveal melanoma].
    Jäckel A; Bock M; Deichmann M; Waldmann V; Näher H
    Hautarzt; 2001 Feb; 52(2):98-103. PubMed ID: 11244899
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Malignant melanoma of the uvea].
    Boaziz C; Mazeron JJ; Morere JF; Breau JL; Israël L
    Bull Cancer; 1993 Jul; 80(7):577-83. PubMed ID: 8204938
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bevacizumab plus fotemustine as first-line treatment in metastatic melanoma patients: clinical activity and modulation of angiogenesis and lymphangiogenesis factors.
    Del Vecchio M; Mortarini R; Canova S; Di Guardo L; Pimpinelli N; Sertoli MR; Bedognetti D; Queirolo P; Morosini P; Perrone T; Bajetta E; Anichini A
    Clin Cancer Res; 2010 Dec; 16(23):5862-72. PubMed ID: 21030496
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Isolated limb perfusion with fotemustine after chemosensitization with dacarbazine in melanoma.
    Pontes L; Lopes M; Ribeiro M; Santos JG; Azevedo MC
    Melanoma Res; 1997 Oct; 7(5):417-9. PubMed ID: 9429225
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A prospective randomized multicentre phase III trial of fotemustine plus whole brain irradiation versus fotemustine alone in cerebral metastases of malignant melanoma.
    Mornex F; Thomas L; Mohr P; Hauschild A; Delaunay MM; Lesimple T; Tilgen W; Bui BN; Guillot B; Ulrich J; Bourdin S; Mousseau M; Cupissol D; Bonneterre ME; De Gislain C; Bensadoun RJ; Clavel M
    Melanoma Res; 2003 Feb; 13(1):97-103. PubMed ID: 12569292
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian Network for Tumor Biotherapy (NIBIT)-M1 phase II study.
    Di Giacomo AM; Ascierto PA; Queirolo P; Pilla L; Ridolfi R; Santinami M; Testori A; Simeone E; Guidoboni M; Maurichi A; Orgiano L; Spadola G; Del Vecchio M; Danielli R; Calabrò L; Annesi D; Giannarelli D; Maccalli C; Fonsatti E; Parmiani G; Maio M
    Ann Oncol; 2015 Apr; 26(4):798-803. PubMed ID: 25538176
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sequential interferon-alpha2b, interleukin-2 and fotemustine for patients with metastatic melanoma.
    Terheyden P; Becker JC; Kämpgen E; Bröcker EB
    Melanoma Res; 2000 Oct; 10(5):475-82. PubMed ID: 11095409
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chemotherapy by fotemustine in cerebral metastases of disseminated malignant melanoma.
    Jacquillat C; Khayat D; Banzet P; Weil M; Avril MF; Fumoleau P; Namer M; Bonneterre J; Kerbrat P; Bonerandi JJ
    Cancer Chemother Pharmacol; 1990; 25(4):263-6. PubMed ID: 2403853
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeting Bcl-2/Bcl-XL induces antitumor activity in uveal melanoma patient-derived xenografts.
    Némati F; de Montrion C; Lang G; Kraus-Berthier L; Carita G; Sastre-Garau X; Berniard A; Vallerand D; Geneste O; de Plater L; Pierré A; Lockhart B; Desjardins L; Piperno-Neumann S; Depil S; Decaudin D
    PLoS One; 2014; 9(1):e80836. PubMed ID: 24454684
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Good clinical activity and favorable toxicity profile of once weekly bortezomib, fotemustine, and dexamethasone (B-MuD) for the treatment of relapsed multiple myeloma.
    Mangiacavalli S; Pochintesta L; Pascutto C; Cocito F; Pompa A; Cazzola M; Corso A
    Am J Hematol; 2013 Feb; 88(2):102-6. PubMed ID: 23224960
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Uveal Melanoma Metastatic to the Liver: Chemoembolization With 1,3-Bis-(2-Chloroethyl)-1-Nitrosourea.
    Gonsalves CF; Eschelman DJ; Thornburg B; Frangos A; Sato T
    AJR Am J Roentgenol; 2015 Aug; 205(2):429-33. PubMed ID: 25905562
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.